| Literature DB >> 35740124 |
Omer Sheriff Sultan1, Haresh Kumar Kantilal2, Suan Phaik Khoo3, Amalraj Fabian Davamani4, Sumaiya Zabin Eusufzai5, Farah Rashid5, Nafij Bin Jamayet1, Jue Ann Soh6, Yen Yee Tan1, Mohammad Khursheed Alam7.
Abstract
This systematic review aims to evaluate the antimicrobial activity of α-mangostin derived from Garcinia mangostana against different microbes. A literature search was performed using PubMed and Science Direct until March 2022. The research question was developed based on a PICO (Population, Intervention, Control and Outcomes) model. In this study, the population of interest was microbes, α-mangostin extracted from Garcinia mangostana was used as exposure while antibiotics were used as control, followed by the outcome which is determined by the antimicrobial activity of α-mangostin against studied microbes. Two reviewers independently performed the comprehensive literature search following the predetermined inclusion and exclusion criteria. A methodological quality assessment was carried out using a scoring protocol and the risk of bias in the studies was analyzed. Reward screening was performed among the selected articles to perform a meta-analysis based on the pre-determined criteria. Case groups where α-mangostin extracted from Garcinia mangostana was incorporated were compared to groups using different antibiotics or antiseptic agents (control) to evaluate their effectiveness. A total of 30 studies were included; they were heterogeneous in their study design and the risk of bias was moderate. The results showed a reduction in microbial counts after the incorporation of α-mangostin, which resulted in better disinfection and effectiveness against multiple microbes. Additionally, the meta-analysis result revealed no significant difference (p > 0.05) in their effectiveness when α-mangostin was compared to commercially available antibiotics. α-mangostin worked effectively against the tested microbes and was shown to have inhibitory effects on microbes with antibiotic resistance.Entities:
Keywords: Garcinia mangostana; antimicrobial; α-mangostin
Year: 2022 PMID: 35740124 PMCID: PMC9219858 DOI: 10.3390/antibiotics11060717
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Chemical structure of a-mangostin.
Keywords used for the search strategy in PubMed.
| Search Words | Results |
|---|---|
| “garcinia” | 1898 |
| “garcinia mangostana” OR (“garcinia” AND “mangostana”) | 540 |
| (“garcinia mangostana” OR (“garcinia” AND “mangostana”) OR “garcinia mangostana”) AND (“mangostin” OR “mangosteen”) | 431 |
| (“garcinia mangostana” OR (“garcinia” AND “mangostana” OR “garcinia mangostana”) AND (“mangostin”) OR “mangosteen”) AND Anti) | 199 |
| ((((garcinia mangostana) OR garcinia)) AND ((((((mangostana) OR garcinia mangostana) OR mangosteen) OR mangostin) OR mangostin) OR alpha mangostin)) AND (((anti-bacterial agents) OR anti-bacterial agents OR anti-bacterial)) AND ((((((agents) OR anti-bacterial agents) OR antibacterial) OR anti-infective agents) OR anti-infective agents OR anti-infective)) AND (((agents) OR anti-infective agents) OR antimicrobial) | 55 |
Newcastle–Ottawa scoring criteria used for meta-analysis.
| Score | Criteria |
|---|---|
| 0 | Inadequate description of case and control group |
| 1 | Studies that used another antimicrobial agent except for antibiotics and antiseptics as the control group |
| 2 | Studies that did not include α-mangostin as a major antimicrobial agent |
| 3 | Studies included in this meta-analysis: |
Articles excluded from this meta-analysis with their reasons for exclusion.
| Author Name (Year) | Title | Reason of Exclusion |
|---|---|---|
| Chokpaisam | Effects of a traditional Thai polyherbal medicine ‘Ya-Samarn-Phlae’ as a natural anti-biofilm agent against | 2 |
| Larsuprom | In vitro antibacterial activity of mangosteen ( | 0 |
| Larsuprom | In vitro antibacterial activity of mangosteen ( | 0 |
| Narasimhan | Anti-bacterial and anti-fungal activity of xanthones obtained via semi-synthetic modification of α-mangostin from | 1 |
| Nguyen | Antibiofilm activity of a-mangostin extracted from | 1 |
| Phitaktim | Synergism and the mechanism of action of the combination of α-mangostin isolated from | 1 |
| Tatiya-Aphiradee | In vivo antibacterial activity of | 1 |
| Mohamed | Mangostanaxanthones I and II, new xanthones from the pericarp of | 0 |
| Asasutjarit | Physicochemical properties and anti-propionibacterium acnes activity of film-forming solutions containing alpha-mangostin-rich extract | 0 |
| Nguen | a-Mangostin disrupts the development of | 1 |
| Samprasit | Mucoadhesive electrospun chitosan-based nanofiber mats for dental caries prevention | 0 |
| Samprasit | Antibacterial activity of | 0 |
| Koh | Rapid bactericidal action of alpha-mangostin against MRSA as an outcome of membrane targeting | 1 |
| Al-Massarani | Phytochemical, antimicrobial, and antiprotozoal evaluation of | 2 |
| Charernsriwilaiwat | Electrospun chitosan-based nanofiber mats loaded with | 0 |
| Seesom | Antileptospiral activity of xanthones from | 2 |
| Arunrattiyakorn | Microbial metabolism of a-mangostin isolated from | 2 |
| Nguyen | Antimicrobial actions of a-mangostin against oral | 0 |
| Pothitirat | Free radical scavenging and anti-acne activities of mangosteen fruit rind extracts prepared by different extraction methods | 0 |
| Pothitirat | Comparison of bioactive compounds content, free radical scavenging, and anti-acne inducing bacteria activities of extracts from the mangosteen fruit rind at two stages of maturity | 0 |
| Chomnawang | Antibacterial activity of Thai medicinal plants against methicillin-resistant | 1 |
| Sakagami | Antibacterial activity of a-mangostin against vancomycin-resistant | 1 |
| Iinuma | Antibacterial Activity of Xanthones from Guttiferaeous Plants against Methicillin-resistant | 1 |
Summary of the screening process.
| Database | Initial Hits | After Screening 1 (Only Research Articles Included) | After Screening 2 (Only | After Screening 3 (Only α-Mangostin Included) | After Screening 4 (Type of Microbe Mentioned) Unique Records |
|---|---|---|---|---|---|
| PUBMED | 55 | 53 | 49 | 33 | 28 |
| Science Direct | 39 | 12 | 12 | 9 | 2 |
| Total | 94 | 65 | 61 | 42 | 30 |
Figure 2Flowchart demonstrating the PRISMA chart. * Records Identified; ** Records Excluded.
Risk of bias of included studies.
| Author of the Study | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chokpaisam et al. (2019) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 2 | Ghasemzadeh et al. (2018) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 3 | Narasimhan et al. (2017) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 0 | 5 |
| 4 | Phitaktim et al. (2016) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 5 | Tatiya-Aphiradee et al. (2016) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 6 | Samprasit et al. (2015) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 7 | Nguyen et al. (2014) | 1 | 1 | 1 | 0 | 0 | na | 1 | unclear | 1 | 5 |
| 8 | Mohamed et al. (2014) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 0 | 5 |
| 9 | Asasutjarit et al. (2014) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 10 | Al-Massarani et al. (2013) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 0 | 5 |
| 11 | Seesom et al. (2013) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 0 | 5 |
| 12 | Charernsriwilaiwat et al. (2013) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 13 | Koh et al. (2013) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 0 | 5 |
| 14 | Arunrattiyakorn et al. (2011) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 0 | 5 |
| 15 | Nguyen et al. (2011) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 0 | 5 |
| 16 | Pothitirat et al. (2010) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 17 | Pothitirat et al. (2009) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 18 | Chomnawang et al. (2009) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 0 | 5 |
| 19 | Sakagami et al. (2005) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 0 | 5 |
| 20 | Iinuma et al. (1996) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 0 | 5 |
| 21 | Phuong et al. (2017) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 22 | Guzmán-Beltrán et al. (2016) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 23 | Kaomongkolgit et al. (2013) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 24 | Nittayananta et al. (2018) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 0 | 5 |
| 25 | Meepagala et al. (2018) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 26 | Larsuprom et al. (2019) | 1 | 1 | 1 | 0 | 0 | na | 1 | unclear | 1 | 5 |
| 27 | Boonnak et al. (2020) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 28 | Suksamsarn et al. (2003) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 29 | Tatiya-aphiradee et al. (2019) | 1 | 1 | 1 | 1 | 0 | na | 1 | unclear | 1 | 6 |
| 30 | Samprasit et al. (2014) | 1 | 1 | 1 | 0 | 0 | na | 1 | unclear | 1 | 5 |
No or unclear: 0 point. Yes: 1-2-3 points for low methodologic quality; 4-5-6 points for moderate methodologic quality; 7-8-9 points for high methodologic quality. na = not applicable.
Figure 3Forest plot of studies on commercially available antibiotics and alpha mangostin.
Characteristics of the studies and their outcomes and results.
| Study ID | Author | Country of Study | Main Antimicrobial Agent | Plant Part Used | Control | Microbes | Method | MIC * of Test | MIC * of Control | MBC **/MFC *** | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inhibitory (mm) | Count | Inhibitory | Count | Test Count (µg/mL) | Control Count (µg/mL) | ||||||||
| 1. | Chokpaisam et al. (2019) [ | Thailand | Ya-Samarn-Phlae (YSP) | Pericarp of | PBS |
| Crystal violet assay | 12.29 μm | - | 18 | - | ||
| 2. | Ghasemzadeh et al. (2018) [ | Malaysia | α-mangostin | Pericarp | Ciprofloxacin | DPPH assay, FRAP assay, | 17, | 18, | |||||
| 3. | Narasimhan et al. (2017) [ | - | α-mangostin and synthetic derivatives | Dried fruits | Ciprofloxacin | Muller Hilton agar plates | 4 | 50 | 11 | 50 | |||
| Ketoconazole | Disc diffusion method | 13 | 100 | ||||||||||
| 4. | Phuong et al. (2017) [ | Vietnam | α-Mangostin | Peels | PBS |
| Membrane activity assay | 4.58–9.15 μmol/L | 2 folds higher | ||||
| 5. | Phitaktim et al. (2016) [ | Thailand | α-mangostin alone and combination with oxacillin and nisin | Matured dried fruit hulls |
|
| MTT assays | 8 | 4 | ||||
| 6. | Tatiya-Aphiradee et al. (2016) [ | Thailand | α- and γ-mangostin | Crude dried pericarp | Gentamicin, Erythromycin | Methicillin-resistant | Agar well diffusion assay | 10 | 0 | 6.25 | >10,000 | 100 | >10,000 |
| 7. | Samprasit et al. (2015) [ | Thailand | α-mangostin | Pericarp | 0.2% | MTT assay | 0.1 mg/mL | 1 mg/mL | 0.2 mg/mL | ||||
| 8. | Nguyen et al. (2014) [ | Vietnam | α-mangostin | Peels |
| F-ATPase and phosphotransferase system (PTS) assays | |||||||
| 9. | Mohamed et al. (2014) [ | Vietnam | Mangostanaxanthones I and II, 9-hydroxycalabaxanthone, parvifolixanthone C, α-mangostin and rubraxanthone | Air-dried pericarps | Ampicillin | Agar plate | 2 | 250 | 24 | - | |||
| Fluconazole | 0 | 20 | NA | NA | |||||||||
| 10. | Asasutjarit et al. (2014) [ | Thailand | α-mangostin | Air-dried rind | Amoxicillin |
| Microdilution assay | 0.5 | 0 | ||||
| 11. | Al-Massarani et al. (2013) [ | Saudi Arabia | α-Mangostin | Pericarp | Amoxifen for MRC-5, chloroquine for | Broth microdilution | NA | >200 µg/mL | NA | NA | NA | NA | |
| 12. | Seesom et al. (2013) [ | Thailand | α-, ϒ-Mangostin | Pericarp | Penicillin |
| Broth microdilution method | 200 to >800 | 0.39 to 6.25 | ||||
| 13. | Charernsriwilaiwat et al. (2013) [ | - | α-Mangostin | Fruit hull | Penicillin | Metal ion chelating assay | 0.5 | 0.5 | |||||
| 14. | Koh et al. (2013) [ | - | 1,5,8-trihydroxy-3-methoxy-2-(3- | Fruit hull | Vancomycin | Methicillin-resistant | SYTOX green assay | 3.125 | 0.78–1.56 | ||||
| 15. | Arunrattiyakorn et al. (2011) [ | - | a-Mangostin (1), | Fruit hull | Rifampicin, streptomycin, isoniazid, and ofloxacin | Green fluorescent protein microplate assay (GFPMA) | 15.24 and 6.75 μm for | 0.36 × 10−2, 1.46 × 10−2, 0.29–0.54, 0.17–0.34, and 1.08–2.16 μm for rifampicin, streptomycin, isoniazid, and ofloxacin, respectively. | |||||
| 16. | Nguyen et al. (2011) [ | Vietnam | α-Mangostin | Peel | α-Mangostin with 25% ethanol |
| F-ATPase and phosphotransferase system (PTS) assays | 70% | |||||
| 17. | Pothitirat et al. (2010) [ | Thailand | α-mangostin | Rind | other extracts (Hex, EtOH, H2O) | Microdilution assay | 15.63, 7.8–15.63 | 3.91 µg/mL | NA | 7.81–500 µg/mL | 15.63 µg/mL | 31.25–(>500) µg/mL | |
| 18. | Pothitirat et al. (2009) [ | Thailand | α-mangostin | Matured rinds | Pure α-mangostin | Microdilution assay | NA | 15.63 for both | NA | 1.95 ( | 15.63 ( | 1.95 ( | |
| Young rinds | Pure α-mangostin | Microdilution assay | NA | 15.63 ( | NA | 31.25 ( | |||||||
| 19. | Chomnawang et al. (2009) [ | Thailand | α-mangostin | Not mentioned | 16 other medicinal plants | Methicillin-resistant | Disc diffusion and microdilution assay | 11.3 ± 0.60 ( | 0.039 mg/mL for all | Not detected to 19.70 ± 0.60 mm | 0.625–(>5) mg/mL | 0.156 for both (mg/mL) | ≥5 mg/mL |
| 20. | Sakagami et al. (2005) [ | - | α-, β- Mangostin | Stem bark | Gentamicin | Vancomycin-resistant | Agar Dilution | NA | 3.13 (α-Mangostin), 25 (β- Mangostin | NA | >100 | NA | NA |
| Methicillin-resistant | Agar Dilution | NA | 6.25 (α-Mangostin), >100 (β- Mangostin | NA | >100 | NA | NA | ||||||
| 21. | Iinuma et al. (1996) [ | Indonesia | α-Mangostin | Dried and ground pericarp | Vancomycin, Gentamycin |
| 1.57–>12.5 | 0.8 (Vancomycin) and 1.57 (Gentamicin) | |||||
|
| Bioassay | 25 | >25 (Vancomycin) and 25 (Gentamicin) | ||||||||||
| 22. | Guzmán-Beltrán et al. (2015) [ | - | α-Mangostin, NDGA | - | Rifampicin at 0.4 μg/mL |
| Colourimetric assay | 250 (NDGA), 62.5 (α-Mangostin) | |||||
| 23. | Kaomongkolgit et al. (2013) [ | Thailand | α-Mangostin | Dried pericarps | NaOCl and CHX |
| MTT assay | 1.97 | 0.15% (NaOCl), 2.5 (CHX) | 3.94 | 0.31% (NaOCl), 5 (CHX) | ||
| 24. | Nittayananta et al. (2018) [ | Thailand | α-Mangostin and/or lawsone methyl ether (2-methoxy-1,4-naphthoquinone) (LME) | Pericarp | Gentamicin |
| Microdilution assay | 625 mg/mL | 0.625 mg/mL | ||||
|
| Microdilution assay | 0.3125 mg/mL | >2.5 mg/mL | ||||||||||
|
| Microdilution assay | 2.5 mg/mL | 2.5 mg/mL | ||||||||||
| 25 | Meepagala et al. (2018) [ | USA | α-mangostinγ-Mangostin(-)-Epicatechin | Pericarp of | Florfenicol |
| MTT assay ALM-00-173 | - | 41.0 | - | 0.36 | - | - |
| 26 | Larsuprom et al. (2019) [ | Thailand | a-mangostin | Pericarp of | Methicillin-susceptible | Broth Microdilution Method | - | 0.53 ± 0.35 µg/mL, | - | - | - | - | |
| 27 | Boonnak et al. (2020) [ | Thailand | a-mangostin and derivatives | CH2Cl2 extracts of the | Vancomycin | MRSA | Not stated | - | 2.34 | 2.34 | - | - | |
| 28. | Suksamsarn et al. (2003) [ | Thailand | (1)a-mangostin | Fruit hulls and the edible arils and seeds of | Rifam picin |
| Microplate Alamar | - | 6.25 | - | 0.003–0.0047, | - | - |
| 29. | Tatiya-aphiradee et al. (2019) [ | Thailand | a-mangostin | Pericarp extract of | Oxacillin | MSSA ATCC 9144 | Micro-dilution method. | - | 3.625 | - | 0.800 | - | - |
| 30. | Samprasit et al. (2014) [ | - | α-Mangostin | - | Oral microbes | Time kill assay | Only abstract available to the researcher | ||||||
* MIC = minimum inhibitory concentration; ** MBC = minimum bactericidal concentration; *** MFC = minimum fungal concentration.